TENX
NASDAQTenax Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$10.86-0.13 (-1.18%)
01:30 PM06:45 PM
News · 26 weeks36+14%
2025-12-072026-05-31
Mix2190d
- SEC Filings10(48%)
- Other5(24%)
- Leadership3(14%)
- Insider2(10%)
- Analyst1(5%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tenax Therapeutics Inc.SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tenax Therapeutics Inc.SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
- INSIDERChief Financial Officer Staab Thomas R Ii was granted 10,000 shares (SEC Form 4)4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
- INSIDERNew insider Staab Thomas R Ii claimed no ownership of stock in the company (SEC Form 3)3 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
- SECSEC Form S-8 filed by Tenax Therapeutics Inc.S-8 - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- SECSEC Form 10-Q filed by Tenax Therapeutics Inc.10-Q - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- SECTenax Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- PRTenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateOn track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team with appointments of Thomas Staab as Chief Financial Officer and Timothy Healey, MBA, as Chief Commercial Officer CHAPEL HILL, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the quarter ended March 31, 2026 and provided an update on its
- PRTenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it has awarded or will award inducement option awards between April 28, 2026 and June 1, 2026 as material inducements to the employment of four non-executive individuals newly hired by the Company in various clinical operations, medical, product development, and commercial roles. The employees received or will receive, in the aggregate, non-qualified stock options to purchase 657,500 shares of the Company's common
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tenax Therapeutics Inc.SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
- PRTenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial OfficerCHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Timothy Healey, MBA, as Chief Commercial Officer (CCO), effective immediately. Mr. Healey is a proven commercial leader who has led several successful drug launches and joins Tenax to oversee its global commercial strategy. "Tim is a transformational commercial leader with a proven ability to translate complex science into successful product launches," said Chris Giordano, President and Chief Exe
- SECSEC Form DEFA14A filed by Tenax Therapeutics Inc.DEFA14A - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- SECSEC Form DEF 14A filed by Tenax Therapeutics Inc.DEF 14A - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- SECSEC Form 8-K filed by Tenax Therapeutics Inc.8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- PRTenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial OfficerMr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Thomas R. Staab, II as Chief Financial Officer (CFO), effective May 11, 2026. Mr. Staab brings over 25 years of leadership experience across management and corporate finance roles in the healthcare industry. He will replace Thomas McGauley, who has served as interim CFO since December 2024. "Tom br
- SECSEC Form EFFECT filed by Tenax Therapeutics Inc.EFFECT - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- SECSEC Form S-3 filed by Tenax Therapeutics Inc.S-3 - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- ANALYSTCantor Fitzgerald initiated coverage on Tenax Therapeutics with a new price targetCantor Fitzgerald initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $35.00
- SECSEC Form 10-K filed by Tenax Therapeutics Inc.10-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- SECTenax Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- PRTenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateAchieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug CHAPEL HILL, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the year ended December 31, 2025 and provided an update on its recent corporate progress. "We are pleased to announce that we have recently achieved our randomization target
- PRTenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare ConferenceCHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference, which is taking place from March 8-11, 2026, in Miami, FL. Details of presentation:Format: Fireside chatParticipants: Chris Giordano, President & Chief Executive Officer; Stuart Rich, M.D., Chief Medical Officer; Douglas Randall, Chief Business OfficerDate and Time: March 10, 2026, at 2:20 p.m. ET The
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tenax Therapeutics Inc.SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
- PRTenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, which is taking place from February 11-12, 2026, in New York, NY. Details of presentation:Format: Fireside chatParticipants: Chris Giordano, President & Chief Executive Officer; Douglas Randall, Chief Business OfficerDate and Time: February 11, 2026, at 12:30 p.m. ET The live and archived webcast of the p
- INSIDERSEC Form 4 filed by Interim CFO Mcgauley Thomas4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
TENX FAQ
6 questionsWhat does Tenax Therapeutics Inc. do?
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company develops levosimendan, which completed a phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction; and Imatinib, a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax...Where does TENX stock trade?
Tenax Therapeutics Inc. (TENX) is listed on NASDAQ.What sector and industry is TENX in?
Tenax Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TENX?
Tenax Therapeutics Inc. has had 5 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $3500.00 price target on 2026-03-17. Recent price targets range from $1600.00 to $3500.00.What companies are similar to TENX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TENX side-by-side with any of them on Quantisnow.How can I track TENX on Quantisnow?
Quantisnow aggregates Tenax Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TENX to receive live email and push alerts on every new disclosure.